Clinical Trials Browser

Completed × INDUSTRY × pasireotide × Clear all

NCT01794793 2024-10-01

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

Phase 4 Completed

337 enrolled 8 charts

DermatologicEndocrineGenitourinaryNET

Acromegaly, Dumping Syndrome, Melanoma, Neoplasms, Pituitary Neoplasms, Prostatic Neoplasms, Neuroendocrine Tumors, Pituitary ACTH Hypersecretion

NCT01563354 2021-04-02

LUNA

Phase 2 Completed

124 enrolled 18 charts

Carcinoma, Neuroendocrine

NCT01364415 2020-12-21

Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)

Phase 1 Completed

Neuroendocrine Tumors

NCT01646684 2020-12-21

Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Pasireotide LAR in Patients With Castration Resistant Prostate Cancer

Phase 1 Completed

Prostatic Neoplasms

NCT01673646 2019-09-16

Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism

Phase 2 Completed

33 enrolled 24 charts

Acromegaly, Gigantism, Growth Disorders, Pituitary Neoplasms

NCT00088595 2012-06-04

Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors

Phase 2 Completed

45 enrolled 10 charts

Carcinoid Tumor, Serotonin Syndrome